Core Viewpoint - Nord Shares (600110.SH) experienced a significant stock price increase of 105.13% from June 16 to June 26, which raised concerns about abnormal trading behavior and potential risks of overheating in trading [1][2]. Group 1: Stock Performance and Financials - The stock price of Nord Shares reached 7.2 yuan, with a market capitalization of 12.493 billion yuan [1]. - The company reported a revenue of 5.277 billion yuan for 2024, reflecting a year-on-year growth of 15.44%, but incurred a net loss of 352 million yuan [2]. - In the first quarter of 2025, the revenue was 1.409 billion yuan, with a net loss of 38 million yuan [2]. Group 2: Business Operations and Market Position - Nord Shares specializes in the research, production, and sales of electrolytic copper foil for lithium-ion batteries, with a minimal contribution of less than 1% of its revenue coming from solid-state battery applications [2]. - The company is developing double-sided nickel-plated copper foil, which is compatible with semi-solid and solid-state battery technologies, but the business remains in its early stages and faces intense market competition [2]. Group 3: Regulatory and Compliance Issues - The company is under investigation by the China Securities Regulatory Commission (CSRC) for potential violations related to information disclosure and undisclosed related-party transactions [3][4]. - Nord Shares has been cooperating with the CSRC during the investigation and has not yet received conclusive opinions or decisions regarding the matters under investigation [3]. - The company is currently verifying whether its actual controllers and directors have undisclosed related-party relationships with Hongtian Shares and is urging relevant parties to clarify any potential connections [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 MODERN INNOVATIVE DIGITAL TECHNOLOGY COMPANY LIMITED （於百慕達註冊成立之有限公司） 新質數字科技有限公司 （股份代號：2322） 截至二零二五年三月三十一日止年度業績公告 新質數字科技有限公司（前稱香港潮商集團有限公司）（「本公司」）董事（「董事」）會 （「董事會」）提呈本公司及其附屬公司（統稱「本集團」）截至二零二五年三月三十一 日止年度之已審核綜合業績，連同上一財政年度之已審核比較數字如下： 1 綜合損益及其他全面收益表 截至二零二五年三月三十一日止年度 | | | 二零二�年 | 二零二四年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 收益 | 3 | 73,706 | 144,950 | | 銷售成本 | | (53,195) | (112,283) | | 毛利 | | 20,511 ...

观察者网消息，路透社26日援引四名贸易消息人士说法称，多家中国饲料制造商已联合签署协议，拟7月 采购3万吨阿根廷大豆豆粕。据悉，这是自2019年中阿签署协议，准许阿根廷大豆豆粕输入中国以来的首 笔订单。 消息人士透露，这批豆粕的成交价格为每吨360美元（成本+运费），预计将在9月运抵中国广东。一家向 中国销售大豆的国际贸易公司驻新加坡的交易员表示，这笔订单只是一次"试水案例"（test case），"如果 能通过中国的检验检疫，我们预计将有更多交易"。 豆粕是大豆榨油后的下脚料，是优良的蛋白质来源，被广泛用于饲料和食品工业等领域。中国是全球最大 的大豆豆粕消费国，阿根廷则是全球最大的豆油和豆粕出口国。 但中国豆粕不主要依赖直接进口，而是大多来自对进口大豆的再加工，而这些进口大豆主要来自巴西和美 国。根据海关总署数据，中国在2024年全年豆粕进口总量仅约3万吨，主要进口来源地是丹麦，且此前没 有从阿根廷大宗采购豆粕的记录。 2025年6月17日，在山东烟台港龙口港区，来自巴西的进口大豆正在卸船 视觉中国 彭博社指出，在中美贸易争端持续之际，中国罕见地从阿根廷订购豆粕，将有助于保障关键动物饲料原料 的供应。前述交 ...

新华社海口6月26日电（记者吴茂辉）海南自由贸易港第20批制度集成创新案例26日发布，涉及教 育、营商环境、文化传承保护等领域的7项改革举措入选本次发布案例。 医保基金结算医药货款省级全域直付。建立适应海南自贸港建设的医药货款结算机制，完善药械采 购管理，扩大医保基金直付范围，破解医药货款拖欠问题，降低医药企业运行成本。 "零关税"进口药品、医疗器械监管服务创新。创新研发园区全链条区块链存证追溯系统，打造医疗 特区监管平台，构建协同推进工作机制，推动"零关税"进口药品、医疗器械政策快速落地实施，促进海 南医药产业高质量发展。 民族文化保护传承发展"标准+服务"体系。依托全国首家黎苗文化为主题的5A级旅游景区，构建民 族文化保护传承发展"标准+服务"体系，为民族文化保护传承发展提供可复制、可推广的实践经验。 疑难复杂营商环境问题法治会诊解决机制。通过12345政务服务热线建立受理平台，构建全省统一 的营商环境问题受理、核实处置、法治会诊、跟踪监督和回访评价体系，以法治会诊破解深层堵点，形 成企业服务闭环，助力打造一流法治化营商环境。 放心消费"在线承诺+动态星级"服务。推行放心消费"在线承诺+动态星级"服务新模 ...

折叠屏现下依然是国产手机厂商们在高端市场与苹果较量的重要筹码。 仅在今年上半年，6月25日vivo对外发布了售价6999元起的新一代大折叠手机X Fold5，小米和荣耀紧接 着也将分别发布自己的小折叠手机MIX Flip2和大折叠手机MagicV5。而早在二三月间，OPPO和华为已 相继发布了大折叠手机FindN5和阔折叠屏手机PuraX。 在国内手机厂商纷纷发布新机的同时，折叠屏手机市场增速正日趋放缓，近日产业链还传出苹果折叠屏 手机可能在明年秋天面世的消息，这除了意味着折叠屏手机市场将更加热闹外，也意味着无论是要"截 胡"苹果手机用户，还是做苹果生态的"搭子"，国产手机厂商们意图转化苹果用户的脚步必须加快了。 折叠屏持续卷 折叠屏手机的普及，离不开工业设计、电池、屏幕等核心零部件的技术突破，也离不开成本和价格的持 续降低。 轻薄一直是折叠屏手机的重要卖点。以vivo新发布的 X Fold5为例，其搭载骁龙8Gen 3芯片，8.03英寸主 屏，但机身最低仅重217克，据vivo介绍，这个数字轻过当下所有大折叠和主流直板旗舰。但在轻薄的 同时，它还成为全球首款"三防"折叠屏手机：IPX9+防水能力、IP5X防 ...

EIA天然气报告：截至6月20日当周，美国天然气库存总量为28980亿立方英尺，较此前一周增加960亿 立方英尺，较去年同期减少1960亿立方英尺，同比降幅6.3%，同时较5年均值高1790亿立方英尺，增幅 6.6%。 天然气期货 ...

Core Viewpoint - Pearson (PSO) has experienced significant selling pressure, resulting in an 11.1% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating a potential rebound for the stock [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with a reading below 30 typically indicating this condition [2]. - PSO's current RSI reading is 28.88, suggesting that the heavy selling may be exhausting itself and a trend reversal could occur soon [5]. - The RSI helps investors identify potential entry points for stocks that have fallen below their fair value due to excessive selling pressure [3]. Group 2: Fundamental Indicators - There has been a consensus among sell-side analysts to raise earnings estimates for PSO, resulting in a 1.2% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [7]. - PSO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which further supports the potential for a turnaround [8].

Group 1 - Catalyst Pharmaceutical (CPRX) has experienced significant selling pressure, resulting in a 12.2% decline over the past four weeks, but analysts expect better earnings than previously predicted [1] - The Relative Strength Index (RSI) for CPRX is currently at 25.06, indicating that the stock is in oversold territory, which may suggest a potential reversal in trend [5][7] - Over the last 30 days, the consensus EPS estimate for CPRX has increased by 0.9%, indicating a positive trend in earnings estimate revisions that typically correlates with price appreciation [7][8] Group 2 - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8]

Core Viewpoint - Hims & Hers Health, Inc. (HIMS) has experienced a significant decline of 22.4% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - HIMS has an RSI reading of 29.06, suggesting that the heavy selling pressure may be exhausting, indicating a potential bounce back towards equilibrium [5]. - Stocks oscillate between overbought and oversold conditions, and the RSI helps identify potential reversal points, making it a useful tool for investors seeking entry opportunities [3]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding HIMS, with a 0.6% increase in the consensus EPS estimate over the last 30 days, indicating a positive outlook for earnings [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term, supporting the case for a potential stock rebound [7]. - HIMS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, further indicating a favorable outlook for the stock [8].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （於百慕達註冊成立之有限公司） （股份代號：00711.HK） 截 至2025年3月31日 止 年 度 之 全 年 業 績 | * | 每 股 | 每 股 | 本 公 | 總 營 | | | 財 務 | | --- | --- | --- | --- | --- | --- | --- | --- | | 每 股 | 權 | 基 | 司 | 業 | | | 摘 | | 權 | 益* | 本 | 股 | 額 | | | 要 | | 益 | | 虧 | 東 | | | | | | 指 | | 損 | 應 | | | | | | 本 | | | 佔 | | | | | | 公 司 | | | 虧 | | | | | | 股 | ...